This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Brand Names
Ytracis
Generic Name
Yttrium Y-90
DrugBank Accession Number
DB13076
Background

Yttrium 90 has been investigated for the treatment of Colon Cancer and Colorectal Cancer.

Type
Small Molecule
Groups
Approved, Investigational
Structure
Thumb
Weight
Average: 89.9072
Monoisotopic: 89.907151443
Chemical Formula
Y
Synonyms
  • Yttrium (90 Y)
  • Yttrium (90Y)
  • Yttrium Y 90
  • Yttrium-90

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
No interactions found.

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Yttrium-90 chlorideTN98A27Q1739271-65-3PCMOZDDGXKIOLL-SGNQUONSSA-K
Yttrium-90 citrateJ8L3BWC4BD67023-60-3YCWCJWQILLXGBP-IEOVAKBOSA-K
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Ytracis1.850 GBq/mlCis Bio International2016-09-08Not applicableEU flag
Yttriga150.05 GBq/mLEckert Ziegler Radiopharma Gmb H2016-09-08Not applicableEU flag
Yttriga150.05 GBq/mLEckert Ziegler Radiopharma Gmb H2020-12-16Not applicableEU flag

Categories

ATC Codes
V10AA01 — Yttrium (90y) citrate colloid
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of inorganic compounds known as homogeneous transition metal compounds. These are inorganic compounds containing only metal atoms,with the largest atom being a transition metal atom.
Kingdom
Inorganic compounds
Super Class
Homogeneous metal compounds
Class
Homogeneous transition metal compounds
Sub Class
Not Available
Direct Parent
Homogeneous transition metal compounds
Alternative Parents
Not Available
Substituents
Homogeneous transition metal
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
1K8M7UR6O1
CAS number
10098-91-6
InChI Key
VWQVUPCCIRVNHF-OUBTZVSYSA-N
InChI
InChI=1S/Y/i1+1
IUPAC Name
(90Y)yttrium
SMILES
[90Y]

References

General References
Not Available
PubChem Compound
104760
PubChem Substance
347829203
ChemSpider
94570

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentArthritis1
3Not Yet RecruitingTreatmentInoperable Hepatocellular Carcinoma1
2Active Not RecruitingTreatmentMalignant Lymphomas1
2RecruitingTreatmentCholangiocarcinomas1
2SuspendedTreatmentHepatocellular Carcinoma1
2WithdrawnTreatmentColorectal Carcinoma (CRC) / Malignant Neoplasm of Colon1
1Active Not RecruitingTreatmentMature T-Cell and NK-Cell Non-Hodgkin Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Mature T- Cell and NK-Cell Non-Hodgkin Lymphoma / Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma / Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma1
1Active Not RecruitingTreatmentRecurrent Adult Hodgkin's Lymphoma1
1CompletedTreatmentCutaneous T Cell Lymphomas (CTCL) / T Cell Leukemia1
1CompletedTreatmentHepatocellular Carcinoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, suspensionIntra-articular
SolutionIntravenous1.85 GBq
SolutionOther1850 MBq
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP0ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity0 m3·mol-1ChemAxon
Polarizability1.78 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at October 21, 2016 02:45 / Updated at March 04, 2021 09:26